This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nimoral

Azanta A/S

Drug Names(s): nimorazole

Description: Nimoral, with the active ingredient nimorazole, is a hypoxic radiosensitizer. Studies have shown that when cancer cells are hypoxic, they are less prone to die upon irradiation. Nimoral mimics oxygen in the target cancer cells allowing them the cells to be more responsive to radiotherapy.

Deal Structure: Azanta and Lavi
In June 2012, Azanta and Lavi announced that they have entered an exclusive agreement for the supply of Nimoral and Zybrestat in Israel. Lavi plans to make Nimoral and Zybrestat available on compassionate use basis. Under the terms of the agreement, Azanta will provide Nimoral and Zybrestat to Lavi at agreed-upon transfer prices. Lavi will serve as Azanta's exclusive distributor for the products in Israel for this purpose.

Azanta and Haemologic
In September 2013, Azanta and Haemologic Ltd entered an exclusive agreement to provide Azanta's products in the United Kingdom. Haemologic expects to make the product line available under the MHRA regulation by supplying to fulfill special patient needs. The portfolio that is now being made available in the United Kingdom consists of Nimoral and Zybrestat. Under the terms of the agreement, Haemologic will make the products available under compassionate use programs.

Azanta and Swedish...See full deal structure in Biomedtracker

Partners: Swedish Orphan Biovitrum Hikma Pharmaceuticals plc


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug